Literature DB >> 29780710

Can we use interleukin-1β blockade for lung cancer treatment?

Adrian Gottschlich1, Stefan Endres1, Sebastian Kobold1.   

Abstract

Entities:  

Year:  2018        PMID： 29780710      PMCID： PMC5943222          DOI： 10.21037/tlcr.2018.03.15

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  21 in total

Review 1.  The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions.

Authors:  Ron N Apte; Shahar Dotan; Moshe Elkabets; Malka R White; Eli Reich; Yaron Carmi; Xiaping Song; Tatyana Dvozkin; Yakov Krelin; Elena Voronov
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

2.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

3.  Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice.

Authors:  M Suganuma; S Okabe; M W Marino; A Sakai; E Sueoka; H Fujiki
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

4.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

Authors:  Paul M Ridker; Jean G MacFadyen; Tom Thuren; Brendan M Everett; Peter Libby; Robert J Glynn
Journal:  Lancet       Date:  2017-08-27       Impact factor: 79.321

Review 5.  Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.

Authors:  Stefano Ugel; Francesco De Sanctis; Susanna Mandruzzato; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

6.  Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma.

Authors:  John A Lust; Martha Q Lacy; Steven R Zeldenrust; Thomas E Witzig; Laurie L Moon-Tasson; Charles A Dinarello; Kathleen A Donovan
Journal:  Am J Hematol       Date:  2016-04-13       Impact factor: 10.047

7.  Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases.

Authors:  Amanda Tufman; Rudolf Maria Huber; Stefanie Völk; Frederic Aigner; Martin Edelmann; Fernando Gamarra; Rosemarie Kiefl; Kathrin Kahnert; Fei Tian; Anne-Laure Boulesteix; Stefan Endres; Sebastian Kobold
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

Review 8.  Cancer immunotherapy beyond immune checkpoint inhibitors.

Authors:  Julian A Marin-Acevedo; Aixa E Soyano; Bhagirathbhai Dholaria; Keith L Knutson; Yanyan Lou
Journal:  J Hematol Oncol       Date:  2018-01-12       Impact factor: 17.388

9.  IL-1 drives breast cancer growth and bone metastasis in vivo.

Authors:  Ingunn Holen; Diane V Lefley; Sheila E Francis; Sarah Rennicks; Steven Bradbury; Robert E Coleman; Penelope Ottewell
Journal:  Oncotarget       Date:  2016-11-15

Review 10.  NLRP3 inflammasome and its inhibitors: a review.

Authors:  Bo-Zong Shao; Zhe-Qi Xu; Bin-Ze Han; Ding-Feng Su; Chong Liu
Journal:  Front Pharmacol       Date:  2015-11-05       Impact factor: 5.810
View more
  5 in total

1.  Innate and adaptive immunity combined for cancer treatment.

Authors:  Sebastian Kobold
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-17       Impact factor: 11.205

2.  Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC).

Authors:  Maja Šutić; Antje Motzek; Gordana Bubanović; Matthias Linke; Ivan Sabol; Oliver Vugrek; Petar Ozretić; Luka Brčić; Sven Seiwerth; Željko Debeljak; Antonija Jakovčević; Zoran Janevski; Dinko Stančić-Rokotov; Andrea Vukić-Dugac; Marko Jakopović; Miroslav Samaržija; Ulrich Zechner; Jelena Knežević
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 3.  Cell death-mediated cytokine release and its therapeutic implications.

Authors:  David E Place; Thirumala-Devi Kanneganti
Journal:  J Exp Med       Date:  2019-06-11       Impact factor: 14.307

Review 4.  Therapeutic Strategies for Targeting IL-1 in Cancer.

Authors:  Adrian Gottschlich; Stefan Endres; Sebastian Kobold
Journal:  Cancers (Basel)       Date:  2021-01-26       Impact factor: 6.639

Review 5.  Functional Signatures in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Sex-Based Differences in Transcriptomic Studies.

Authors:  Irene Pérez-Díez; Marta R Hidalgo; Pablo Malmierca-Merlo; Zoraida Andreu; Sergio Romera-Giner; Rosa Farràs; María de la Iglesia-Vayá; Mariano Provencio; Atocha Romero; Francisco García-García
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.